Clinical Review Report: sarilumab (Kevzara) [Internet]

Clinical Review Report: sarilumab (Kevzara) [Internet]

Review

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 May.

PMID: 30489709
Bookshelf ID: NBK534411

Excerpt

The objective of this report is to provide a systematic review of the beneficial and harmful effects of sarilumab for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more biologic or non-biologic disease-modifying antirheumatic drugs (DMARDs).

[Table: see text]

Sections

Abbreviations
Executive Summary
1. Introduction
2. Objectives and Methods
3. Results
4. Discussion
5. Conclusions
APPENDIX 1. Patient Input Summary
APPENDIX 2. Literature Search Strategy
APPENDIX 3. Dosage Adjustment for Sarilumab and Tocilizumab
APPENDIX 4. Detailed Outcome Data
APPENDIX 5. Summary of the Extend Extension Study
APPENDIX 6. Summary of Manufacturer’s Indirect Comparison
References

Publication types

Review